<DOC>
	<DOCNO>NCT02369016</DOCNO>
	<brief_summary>Assess efficacy safety copanlisib monotherapy</brief_summary>
	<brief_title>Phase III Copanlisib Rituximab-refractory iNHL</brief_title>
	<detailed_description>Double blind copanlisib v placebo unblinding centrally assess progression option cross copanlisib patient progress placebo .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm diagnosis indolent Bcell NHL , histological subtype limit follow : Follicular lymphoma ( FL ) grade 123a . Small lymphocytic lymphoma ( SLL ) absolute lymphocyte count &lt; 5 x 109/L time diagnosis study entry . Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia ( LPL/WM ) . Marginal zone lymphoma ( MZL ) ( splenic , nodal , extranodal ) . Patients must receive two prior line treatment . A previous regimen define one following : least two month singleagent therapy , least two consecutive cycle polychemotherapy , autologous transplant , radioimmunotherapy . Prior therapy must include rituximab alkylating agent . Prior exposure idelalisib PI3K ( Phosphatidylinositol 3kinase ) inhibitor acceptable ( except copanlisib ) provide resistance . Patients must refractory last rituximabbased treatment , define response response last &lt; 6 month completion treatment . Time interval ass refractoriness calculate end date ( last day ) last rituximabcontaining regimen day diagnosis confirmation subsequent relapse . Patients must least one bidimensionally measurable lesion ( previously irradiate ) accord Recommendations Initial Evaluation , Staging , Response Assessment Hodgkin NonHodgkin Lymphoma : The Lugano Classification . Patients affect WM ( Waldenström macroglobulinemia ) , least one bidimensionally measurable lesion baseline radiologic assessment , must measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level ≥ 2 x upper limit normal ( ULN ) positive immunofixation test . Histologically confirm diagnosis FL grade 3b . Chronic lymphocytic leukemia ( CLL ) . Transformed disease ( assessed investigator ) : histological confirmation transformation , clinical laboratory sign : rapid disease progression , high standardize uptake value ( SUV ) ( &gt; 12 ) positron emission tomography ( PET ) baseline PET scan perform ( optional ) . Previous concurrent cancer distinct primary site histology indolent Bcell NHL within 5 year start study treatment except curatively treated cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor [ Ta ( noninvasive tumor ) , Tis ( carcinoma situ ) T1 ( tumor invades lamina propria ) ] Bulky disease Lymph nod tumor mass ( except spleen ) &gt; = 7cm LD ( long diameter ) Known lymphomatous involvement central nervous system . Uncontrolled arterial hypertension despite optimal medical management ( per investigator 's assessment ) . Type I II diabetes mellitus HbA1c &gt; 8.5 % Screening . Known history human immunodeficiency virus ( HIV ) infection . Positive cytomegalovirus ( CMV ) PCR test baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>indolent Non-Hodgkin lymphoma</keyword>
	<keyword>rituximab-refractory</keyword>
</DOC>